Synimmune (Biotechnology) Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Synimmune (Biotechnology) General Information

Description

Operator of a biotechnology company intended to develop oncology products. The company's services provide research and development of immunotherapies, provides monoclonal TCR technology to facilitate the generation of novel tumor-specific TCRs for the development of adoptive T cell therapy, and also provides an antigen discovery platform for functional identification of neoantigens for the development of personalized cancer vaccines, enabling physicians and doctors to treat their patients with various types of cancer.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Corporate Office
  • 865 Altaire Walk
  • Palo Alto, CA 94303
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Drug Delivery
Vertical(s)
Corporate Office
  • 865 Altaire Walk
  • Palo Alto, CA 94303
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synimmune (Biotechnology) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 25-May-2021 Completed Out of Business
1. Accelerator/Incubator Completed Startup
To view Synimmune (Biotechnology)’s complete valuation and funding history, request access »

Synimmune (Biotechnology) Patents

Synimmune (Biotechnology) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2020192684-A1 Therapeutic agent containing isolated recombinant oncolytic adenovirus and immune cells and use therefor Inactive 27-Mar-2019
WO-2020038491-A1 Isolated t-cell receptor, modified cell, encoding nucleic acid and use thereof Inactive 24-Aug-2018
WO-2020038492-A1 Therapeutic agent comprising nucleic acid and tcr modified immune cell and use thereof Inactive 24-Aug-2018
WO-2019096115-A1 Isolated t-cell receptor, cell modified by same, coding nucleic acids, expression vector, preparation method, pharmaceutical composition, and applications Inactive 14-Nov-2017

Synimmune (Biotechnology) FAQs

  • When was Synimmune (Biotechnology) founded?

    Synimmune (Biotechnology) was founded in 2017.

  • Where is Synimmune (Biotechnology) headquartered?

    Synimmune (Biotechnology) is headquartered in Palo Alto, CA.

  • What industry is Synimmune (Biotechnology) in?

    Synimmune (Biotechnology)’s primary industry is Biotechnology.

  • Is Synimmune (Biotechnology) a private or public company?

    Synimmune (Biotechnology) is a Private company.

  • What is Synimmune (Biotechnology)’s current revenue?

    The current revenue for Synimmune (Biotechnology) is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process